Federal authorities on Thursday announced initial funding to examine the clinical potential of ibogaine, a controversial psychedelic compound supported by veterans, conservative lawmakers, and podcasters allied with President Donald Trump.
Health Secretary Robert F. Kennedy Jr. confirmed the department will provide up to $4.9 million to prepare for the first U.S. trials evaluating ibogaine for post-traumatic stress disorder, a difficult condition tied to elevated suicide and substance abuse among veterans.